A Phase 1a/1b Dose Escalation and Dose Expansion Study of NPX887 in Participants With Solid Tumor Malignancies Known to Express HHLA-2/B7-H7

Status: Recruiting

Phase of Trial: Phase I

Latest Information Update: 10 Mar 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs NPX-887 (Primary)
Indications Adenocarcinoma; Biliary cancer; Carcinoma; Colorectal cancer; Gastric cancer; Lung cancer; Non-small cell lung cancer; Oesophageal cancer; Ovarian cancer; Renal cell carcinoma; Small cell lung cancer; Solid tumours
Focus Adverse reactions; First in man; Therapeutic Use
Sponsors NextPoint Therapeutics

16 Oct 2024 Protocol amended with addition of preliminary efficacy endpoints along with safety of drug. Hence trial focus becomes TU and AR.
20 Feb 2024 According to a NextPoint Therapeutics media release, company announced that the first patient has been dosed with NPX887 in a Phase 1 first-in-human clinical trial for the treatment of patients with solid tumors expressing HHLA2/B7-H7.
06 Feb 2024 Status changed from planning to recruiting.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com